Table 2.
Hazard Ratios for associations between N Terminal pro-B natriuretic peptide and mortality, ARIC, 1996-2008
| Hazard ratio (95% Confidence Interval) |
||||||
|---|---|---|---|---|---|---|
| ≤ 27.4pg/ml | 27.5-52.3pg/ml | 52.4-88.6pg/ml | 88.7-158.0pg/ml | ≥159pg/ml | P for trend | |
| N | 2240 | 2244 | 2239 | 2233 | 2237 | |
| Total mortality (n=1909) Events | 208 | 256 | 342 | 350 | 753 | |
| Model 1 | 1 | 1.28 (1.06- 1.55) | 1.80 (1.51- 2.16) | 1.92 (1.60- 2.30) | 3.87 (3.27- 4.58) | <0.0001 |
| Model 2 | 1 | 1.33 (1.07- 1.65) | 1.78 (1.43- 2.20) | 1.92 (1.55- 2.38) | 3.05 (2.46- 3.77) | <0.0001 |
| Model 3 | 1 | 1.26 (1.01- 1.57) | 1.63 (1.32- 2.02) | 1.74 (1.40- 2.16) | 2.46 (1.98- 3.05) | <0.0001 |
| All CVD mortality (n= 358) Events | 33 | 51 | 67 | 62 | 145 | |
| Model 1 | 1 | 1.77 (1.14- 2.75) | 2.57 (1.68- 3.93) | 2.70 (1.75- 4.18) | 7.33 (4.92- 10.9) | <0.0001 |
| Model 2 | 1 | 1.99 (1.20- 3.29) | 3.03 (1.87- 4.92) | 2.77 (1.67- 4.60) | 7.48 (4.67- 12.0) | <0.0001 |
| Model 3 | 1 | 1.81 (1.09- 2.99) | 2.55 (1.57- 4.14) | 2.27 (1.37- 3.78) | 5.10 (3.16- 8.22) | <0.0001 |
| CHD mortality (n= 138) Events | 18 | 25 | 28 | 15 | 52 | |
| Model 1 | 1 | 1.52 (0.82- 2.80) | 1.86 (1.01- 3.42) | 1.12 (0.55- 2.27) | 4.44 (2.50- 7.88) | <0.0001 |
| Model 2 | 1 | 1.55 (0.78- 3.11) | 2.01 (1.02- 3.98) | 1.11 (0.49- 2.47) | 4.07 (2.07- 7.98) | 0.0002 |
| Model 3 | 1 | 1.43 (0.71- 2.86) | 1.73 (0.87- 3.43) | 0.93 (0.41- 2.07) | 2.81 (1.41- 5.60) | 0.01 |
| Stroke mortality (n= 67) Events | 3 | 9 | 13 | 13 | 29 | |
| Model 1 | 1 | 2.95 (0.79- 11.0) | 4.38 (1.23- 15.6) | 4.64 (1.29- 16.7) | 12.0 (3.52- 41.1) | <0.0001 |
| Model 2 | 1 | 3.87 (0.81- 18.4) | 5.91 (1.29- 27.1) | 4.50 (0.93- 21.8) | 10.4 (2.26- 47.7) | 0.001 |
| Model 3 | 1 | 3.61 (0.76- 17.2) | 5.34 (1.17- 24.5) | 4.02 (0.83- 19.5) | 7.76 (1.67- 36.2) | 0.01 |
| Cancer Mortality (n= 502) Events | 86 | 98 | 103 | 99 | 116 | |
| Model 1 | 1 | 1.13 (0.84- 1.52) | 1.24 (0.92- 1.68) | 1.20 (0.88- 1.63) | 1.41 (1.04- 1.93) | 0.04 |
| Model 2 | 1 | 1.13 (0.82- 1.56) | 1.21 (0.87- 1.70) | 1.25 (0.89- 1.76) | 1.39 (0.97- 2.00) | 0.07 |
| Model 3 | 1 | 1.12 (0.81- 1.55) | 1.19 (0.85- 1.66) | 1.22 (0.86- 1.72) | 1.30 (0.90- 1.88) | 0.16 |
| Respiratory disease mortality (n= 99) Events | 8 | 13 | 24 | 23 | 31 | |
| Model 1 | 1 | 1.52 (0.62- 3.68) | 2.98 (1.32- 6.77) | 2.78 (1.20- 6.44) | 3.36 (1.46- 7.72) | 0.001 |
| Model 2 | 1 | 1.48 (0.49- 4.48) | 2.45 (0.86- 7.04) | 2.99 (1.05- 8.49) | 2.02 (0.67- 6.09) | 0.12 |
| Model 3 | 1 | 1.33 (0.44- 4.06) | 2.15 (0.75- 6.17) | 2.59 (0.91- 7.38) | 1.45 (0.48- 4.43) | 0.37 |
CHD- indicates coronary heart disease, CVD- indicates cardiovascular disease, P for linear trend across quintiles
Model 1- adjusted for age, sex and race
Model 2- adjusted for model 1 + body mass index, total cholesterol, high density lipoprotein cholesterol, diet, sport index, smoking status, drinking status, hormone use, systolic blood pressure, antihypertensive medication, diabetes, forced expiratory volume in 1 second/forced vital capacity predicted %, estimated glomerular filtration rate. In addition, total mortality was adjusted for history of cancer, CVD, stroke, heart failure and respiratory disease
Model 3- adjusted for model 2 + high sensitivity C- reactive protein (Hs-CRP) and troponin T